Jepson Rosanne E, Elliott Jonathan, Brodbelt David, Syme Harriet M
Department of Veterinary Basic Science, Royal Veterinary College, Camden, London, UK.
J Vet Intern Med. 2007 May-Jun;21(3):402-9. doi: 10.1892/0891-6640(2007)21[402:eocosb]2.0.co;2.
Systemic hypertension is a common clinical problem, often occurring in association with renal disease in cats. Limited information is available to assess the effect of blood pressure and the treatment of hypertension on survival.
That adequacy of blood pressure control is associated with the duration of survival in cats with systolic hypertension.
One hundred and forty-one client-owned cats with systolic hypertension.
Hypertensive cats were treated with amlodipine besylate and were followed until death or the study end point. Time-averaged systolic blood pressure (SBPOT) after implementation of antihypertensive medication and stabilization of systolic blood pressure (SBP) was calculated by using the equation (area under the curve/survival [days]). Cats were divided into quartiles based on their SBPOT, representing varying levels of blood pressure control (median [25th, 75th percentile]: Q1 = 137 [132, 141] mm Hg, Q2 = 148 [145, 151] mm Hg, Q3 = 157 [155, 158] mm Hg, Q4 = 170 [164, 175] mm Hg). Survival and clinical variables were compared between the quartiles. Cox proportional hazard regression analysis was used to determine the association of age, renal function, proteinuria, SBPOT, and the presence of hyperthyroidism on survival. Urine protein to creatinine ratio (UP:C) was compared at diagnosis of hypertension and after initiating treatment.
Only UP:C and SBP at diagnosis differed significantly between SBPOT quartiles. Proteinuria was the only variable significantly related to survival in hypertensive cats. A significant decline in UP:C was found in cats treated with amlodipine besylate.
Proteinuria before and after treatment of hypertension is strongly associated with survival in cats with systolic hypertension. Treatment with amlodipine besylate can result in a significant reduction in UP: C.
系统性高血压是一个常见的临床问题,在猫中常与肾脏疾病相关。关于血压及高血压治疗对生存影响的评估信息有限。
收缩期高血压猫的血压控制是否充分与生存时长相关。
141只客户自有的收缩期高血压猫。
给高血压猫使用苯磺酸氨氯地平进行治疗,并随访至死亡或研究终点。通过使用公式(曲线下面积/生存天数)计算实施抗高血压药物治疗且收缩压(SBP)稳定后的时间平均收缩压(SBPOT)。根据SBPOT将猫分为四分位数,代表不同程度的血压控制水平(中位数[第25、75百分位数]:Q1 = 137[132, 141]mmHg,Q2 = 148[145, 151]mmHg,Q3 = 157[155, 158]mmHg,Q4 = 170[164, 175]mmHg)。比较四分位数之间的生存情况和临床变量。采用Cox比例风险回归分析来确定年龄、肾功能、蛋白尿、SBPOT和甲状腺功能亢进症的存在与生存的关联。在高血压诊断时和开始治疗后比较尿蛋白与肌酐比值(UP:C)。
仅诊断时的UP:C和SBP在SBPOT四分位数之间存在显著差异。蛋白尿是与高血压猫生存显著相关的唯一变量。使用苯磺酸氨氯地平治疗的猫中,UP:C显著下降。
高血压治疗前后的蛋白尿与收缩期高血压猫的生存密切相关。苯磺酸氨氯地平治疗可导致UP:C显著降低。